HIGHLIGHTS
- who: L. Musacchio from the Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, RomeOncology Unit, Marche Polytechnic University, Ancona have published the research work: Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?, in the Journal: (JOURNAL)
- what: This study was designed to assess the efficacy and toxicity of durvalumab, bevacizumab, and olaparib combination in OC patients with platinum-sensitive and platinumresistant recurrence. The results of this trial demonstrate a lack of a survival benefit for the combination of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.